ZA200900316B - Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders - Google Patents

Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders

Info

Publication number
ZA200900316B
ZA200900316B ZA200900316A ZA200900316A ZA200900316B ZA 200900316 B ZA200900316 B ZA 200900316B ZA 200900316 A ZA200900316 A ZA 200900316A ZA 200900316 A ZA200900316 A ZA 200900316A ZA 200900316 B ZA200900316 B ZA 200900316B
Authority
ZA
South Africa
Prior art keywords
edg
antagonists
receptors
prevention
treatment
Prior art date
Application number
ZA200900316A
Other languages
English (en)
Inventor
Debra L Fleenor
Allan R Shepard
Lok-Hou Pang
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200900316B publication Critical patent/ZA200900316B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200900316A 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders ZA200900316B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
ZA200900316B true ZA200900316B (en) 2010-05-26

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900316A ZA200900316B (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders

Country Status (11)

Country Link
US (2) US20080025973A1 (https=)
EP (1) EP2068856A2 (https=)
JP (1) JP2009544734A (https=)
KR (1) KR20090033886A (https=)
CN (1) CN101505744A (https=)
AU (1) AU2007279311A1 (https=)
BR (1) BRPI0714593A2 (https=)
CA (1) CA2657480A1 (https=)
MX (1) MX2009000907A (https=)
WO (1) WO2008014338A2 (https=)
ZA (1) ZA200900316B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014329B (zh) 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2009001457A (es) * 2006-08-08 2009-02-19 Kyorin Seiyaku Kk Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
JP5188972B2 (ja) * 2006-08-08 2013-04-24 杏林製薬株式会社 アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
WO2009117335A2 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
US20120071448A1 (en) * 2009-05-05 2012-03-22 Allergan, Inc. S1P3 Receptor Inhibitors for Treating Conditions of the Eye
US20110039900A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
BR112012006965A2 (pt) * 2009-09-30 2017-08-29 Stiefel Res Australia Pty Ltd Cosmético sob a forma de espuma
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8107694A (en) * 1993-11-17 1995-06-06 Byk Nederland Bv Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
WO2001058468A1 (en) * 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
CA2533587A1 (en) * 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
JP2008522977A (ja) * 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
US8546452B2 (en) * 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Also Published As

Publication number Publication date
US20080025973A1 (en) 2008-01-31
WO2008014338A2 (en) 2008-01-31
CA2657480A1 (en) 2008-01-31
BRPI0714593A2 (pt) 2013-05-07
MX2009000907A (es) 2009-02-04
EP2068856A2 (en) 2009-06-17
JP2009544734A (ja) 2009-12-17
WO2008014338A3 (en) 2008-12-24
US20100183629A1 (en) 2010-07-22
CN101505744A (zh) 2009-08-12
KR20090033886A (ko) 2009-04-06
AU2007279311A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ZA200900316B (en) Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders
WO2007112322A3 (en) Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
SI2019683T1 (sl) Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
IL191283A (en) Compositions for treating eye irregularities
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
EP1879623A4 (en) GENE THERAPY FOR BACKMARK DISEASES
PL1881823T3 (pl) Kompozycje i sposoby leczenia chorób oczu
PT2418201E (pt) Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central
IL180108A0 (en) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders
WO2007141284A3 (en) Treatment of gastrointestinal disorders with cgrp antagonists
IL198005A0 (en) Ccr2 antagonists for treatment of fibrosis
PL1706113T3 (pl) Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
WO2007146349A3 (en) Cgrp receptor antagonists
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
EP2064347A4 (en) METHODS FOR THE IDENTIFICATION, EVALUATION AND TREATMENT OF PATIENTS WITH DC CHIMIOKINE RECEPTOR 2 (CCR-2) MEDIATION DISORDERS
SG138567A1 (en) Punctal plugs for the delivery of active agents
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
IL197876A0 (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
WO2007090134A3 (en) Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma